A 32-year-old pregnant woman (G2P1) at 28 weeks of gestation comes to the pediatric clinic for a prenatal consultation. She has a known diagnosis of Systemic Lupus Erythematosus (SLE) for 8 years. Her disease is currently moderately active. She is taking hydroxychloroquine 200 mg twice daily and prednisolone 10 mg daily. Her laboratory tests show positive anti-Ro/SSA antibodies (high titer) and anti-La/SSB antibodies. She is very anxious and asks:
"Doctor, I am very scared for my baby. I know that lupus can affect the baby's heart. Will my baby have a heart problem? What is neonatal lupus? Can the medicines I take harm my baby? Will my baby need a pacemaker? What about breastfeeding? Please tell me everything."
She has one previous healthy child (now 6 years old) with no medical problems. The father is healthy with no autoimmune disease.
Task for the candidate: You are the pediatrician. Counsel the mother about neonatal lupus syndrome, focusing on the risk of congenital heart block (CHB), neonatal lupus rash, hematologic abnormalities (thrombocytopenia, neutropenia, anemia), the role of anti-Ro/SSA and anti-La/SSB antibodies, fetal monitoring (fetal echocardiography), neonatal management, prognosis, and breastfeeding safety. The examiner will observe your interaction and communication skills.
π‘ Examiner instruction (interactive β observed counseling):
β’ The candidate must demonstrate empathy, active listening, and clear communication.
β’ Use simple, non-technical language initially, then introduce terms appropriately.
β’ Address the mother's anxiety first ("Your fears are completely understandable. We will monitor your baby very closely").
β’ Explain: Neonatal lupus is not SLE in the baby β it is a passive transfer of maternal autoantibodies (anti-Ro/SSA, anti-La/SSB) across the placenta.
β’ Discuss the three main manifestations:
1. Congenital heart block (CHB) β most serious (risk ~1-5% if mother has anti-Ro/La). Complete heart block is irreversible and may require a pacemaker.
2. Neonatal lupus rash β photosensitive, annular, scaly rash on face/scalp; resolves by 6-8 months without scarring.
3. Hematologic abnormalities β thrombocytopenia, neutropenia, anemia (usually transient, resolves by 3-6 months).
β’ Discuss fetal monitoring: serial fetal echocardiography (weekly or biweekly from 16-28 weeks, especially 16-24 weeks when CHB typically develops).
β’ Discuss management: If isolated rash or cytopenias β observation, sun avoidance. If CHB β may require pacemaker (most need it by childhood).
β’ Discuss breastfeeding: hydroxychloroquine and prednisolone are safe in breastfeeding.
β’ Discuss long-term prognosis: Most babies do well aside from CHB. If no heart block by birth, risk of developing it later is very low.
β’ The examiner will then ask the candidate specific questions from the Q&A tab.
π¬ Model Counseling Script β Candidate's Interaction with Mother
π£οΈ Candidate's structured counseling (to be delivered to the mother):
1. Acknowledge and empathize:
βThank you for coming in. I understand how worried you are. Having lupus and being pregnant is already challenging, and the fear of your baby being affected is very real. You are doing the right thing by planning ahead. We will work together to give your baby the best possible care.β
2. Explain what neonatal lupus is (and is not):
βFirst, let me reassure you: neonatal lupus is NOT the same as SLE. Your baby will not have lupus as you know it. Instead, it happens because your antibodies (called anti-Ro and anti-La) cross the placenta and can temporarily affect the babyβs heart, skin, or blood counts. These antibodies are not harmful to you, but they can affect the baby because the babyβs immune system is still developing.β
3. Discuss the risk and the most serious problem β heart block:
βThe most serious concern is a heart rhythm problem called congenital heart block. This happens in about 1-2% of babies born to mothers with your antibodies. In some studies, the risk is up to 5% if the antibodies are very high. Heart block means the electrical signal that controls the heartbeat does not pass normally from the upper to the lower chambers. The heart rate becomes slow β too slow to pump blood effectively.β
4. Explain fetal monitoring (echocardiography):
βBecause of this risk, we will monitor your babyβs heart very closely. Starting around 16-18 weeks of pregnancy, you will have a special ultrasound of the babyβs heart called a fetal echocardiogram. We will do this every 1-2 weeks until about 28-30 weeks, because that is the time when heart block usually develops. If we see any early signs, we may consider medications (like dexamethasone) to try to prevent complete heart block, though this is still being studied.β
5. Discuss other manifestations (rash and blood problems):
βEven if the babyβs heart is normal, they may develop a rash β red, ring-shaped patches on the face, scalp, or body. This rash is not dangerous, and it goes away completely by 6-8 months of age without scarring. We simply need to keep the baby out of direct sunlight (use sunscreen and protective clothing). Some babies also have temporary low platelets (thrombocytopenia) or low white blood cells (neutropenia), but these also resolve on their own. They very rarely cause bleeding problems.β
6. Discuss treatment if heart block occurs:
βIf the baby is born with complete heart block, the heart rate will be slow (usually 50-70 beats per minute). Many babies with this condition need a pacemaker β a small device placed under the skin that helps the heart beat at a normal rate. The pacemaker can be placed soon after birth or within the first few years of life. With a pacemaker, most children live normal lives, play sports, and go to school. Without a pacemaker, some children may have fainting spells or heart failure, so we monitor very closely.β
7. Discuss medicines and breastfeeding:
βYou asked about your medicines. Hydroxychloroquine is very safe during pregnancy and breastfeeding β in fact, it reduces the risk of heart block and is recommended for all pregnant women with lupus who have anti-Ro antibodies. Prednisolone is also safe at your dose. Both medicines pass into breast milk in very small amounts and are considered safe. We strongly encourage breastfeeding β it is good for both you and your baby.β
8. Discuss prognosis and long-term outlook:
βHere is the most important thing: if your baby is born with a normal heart rhythm, the chance of developing heart block later is extremely low (almost zero). The antibodies disappear from the babyβs blood by 6-8 months of age. The rash and blood problems always go away. Children who have a pacemaker for heart block generally do very well, but they do need lifelong cardiology follow-up.β
9. Summarize and close:
βTo summarize: Your baby has a small risk (about 1-5%) of developing a slow heart rhythm (heart block). We will monitor the babyβs heart every 1-2 weeks starting at 16 weeks. If the heart block occurs, a pacemaker may be needed. The baby may also have a temporary rash or low blood counts, which resolve without treatment. Your medicines are safe, and breastfeeding is encouraged. You are not alone β we will have a team including cardiology, rheumatology, and neonatology to support you and your baby. Please continue your medications and let me know if you have any more questions.β
π Examiner observation points (communication skills):
β’ Did the candidate demonstrate empathy and validate the motherβs concerns?
β’ Did they explain that neonatal lupus is NOT SLE and is transient?
β’ Did they correctly state the risk of congenital heart block (1-5%)?
β’ Did they discuss the need for serial fetal echocardiography (16-28 weeks)?
β’ Did they explain the rash and cytopenias as benign, self-limited conditions?
β’ Did they discuss pacemaker therapy honestly but without causing panic?
β’ Did they reassure about safety of hydroxychloroquine and prednisolone during breastfeeding?
β’ Did they mention that antibodies clear by 6-8 months?
β’ Did they provide a clear plan and involve a multidisciplinary team?
β’ Did they provide reassurance and avoid judgment?
π Examiner Questions (after counseling) β Click to reveal model answers
β Q1 (Examiner): βExplain the pathophysiology of neonatal lupus syndrome. Which antibodies are responsible and how do they cause disease?β
β Candidate's answer:
β’ Causative antibodies:Anti-Ro/SSA (60 kD and 52 kD) and anti-La/SSB antibodies β IgG class that cross the placenta from the second trimester onward.
β’ Pathophysiology in the fetus:
- These antibodies bind to fetal tissues that express Ro/La antigens (heart, skin, liver, hematopoietic cells).
- In the heart, they bind to calcium channels in the developing conduction system (atrioventricular node and Purkinje fibers) β inflammation, fibrosis, and scarring of the AV node β complete heart block (third-degree AV block) which is irreversible.
- In the skin, antibody binding causes photosensitivity and an inflammatory response β annular, erythematous, scaly plaques (neonatal lupus rash).
- In the bone marrow/liver, antibodies can cause transient cytopenias (thrombocytopenia, neutropenia, anemia) and mild transaminitis.
β’ The mother herself is not affected by these antibodies (she has SLE but the antibodies are part of her disease). The condition is passive transfer, not active autoimmunity in the infant.
β’ Maternal antibodies are cleared from the infantβs circulation by 6-8 months of age β manifestations resolve (except permanent heart block).
β Q2 (Examiner): βWhat is the risk of congenital heart block (CHB) in an infant born to a mother with anti-Ro/SSA antibodies? Does the titer matter?β
β Candidate's answer:
β’ Overall risk: Approximately 1-2% for any pregnancy in a mother with anti-Ro/SSA antibodies. Some studies report up to 5% in high-risk groups.
β’ Risk increases with:
- High antibody titers (especially anti-Ro52).
- Previous child with CHB: recurrence risk ~15-20%.
- Maternal hypothyroidism or other autoimmune features.
β’ Low risk: If mother has anti-Ro/La antibodies but has never had a child with CHB, the risk for each pregnancy is low (1-2%).
β’ Titer matters: Higher titers (e.g., >80-100 U/mL) confer higher risk, but CHB can occur even with low titers. Negative antibodies (anti-Ro/La negative) carry no risk.
β’ The majority of babies (98-99%) are unaffected.
β Q3 (Examiner): βWhat is the recommended protocol for fetal echocardiography in a pregnancy with maternal anti-Ro/SSA antibodies? When should it start and end?β
β Candidate's answer:
β’ Start:16-18 weeks of gestation (complete heart block rarely develops before 16 weeks).
β’ Frequency:Weekly or every 2 weeks from 16 to 28 weeks, because most CHB develops between 18 and 24 weeks. After 28 weeks, risk is very low.
β’ Technique: Fetal echocardiography with PR interval measurement (mechanical PR interval) β prolonged PR interval (>150 ms) suggests first-degree heart block, which may progress to complete block.
β’ If PR interval is normal: Continue monitoring until 28 weeks.
β’ If first-degree block (PR prolongation) is detected: Consider maternal therapy with dexamethasone (which crosses placenta) to attempt to prevent progression, though evidence is mixed. Repeat echo in 24-48 hours.
β’ If complete heart block develops: Monitor for hydrops, fetal heart failure. Delivery planning at a tertiary center with neonatal cardiology and pacing capability.
β’ After 28 weeks: Monthly monitoring until delivery (though risk is very low).
β’ Some centers also perform a postnatal ECG and Holter monitor even if fetal echos were normal.
β Q4 (Examiner): βCan congenital heart block be treated in utero? What medications are used and what are the risks?β
β Candidate's answer:
β’ Dexamethasone (a fluorinated corticosteroid that crosses the placenta, unlike prednisolone) is used in an attempt to prevent progression from first-degree to complete heart block and to treat associated myocarditis or hydrops.
β’ Indications for maternal dexamethasone:
- Prolonged PR interval (>150 ms) on fetal echocardiography (first-degree block).
- Fetal myocarditis, hydrops, or effusions.
- It is NOT effective once complete heart block is established (the fibrosis is irreversible).
β’ Risks of dexamethasone:
- Maternal: hyperglycemia, hypertension, weight gain, Cushingoid features, osteoporosis with prolonged use.
- Fetal/neonatal: intrauterine growth restriction (IUGR), adrenal suppression, oligohydramnios.
- Long-term: potential neurodevelopmental effects (limited data).
β’ Other therapies (experimental): Intravenous immunoglobulin (IVIG) β some studies show reduced recurrence in mothers with a prior affected child, but not conclusively proven.
β’ Hydroxychloroquine (HCQ) β given throughout pregnancy; reduces the risk of CHB by ~50% in mothers with anti-Ro antibodies (observational data).
β’ Conclusion: Prevention with HCQ is key; dexamethasone may be used in early first-degree block but has significant risks.
β Q5 (Examiner): βDescribe the skin manifestations of neonatal lupus. How is it treated and what is the prognosis?β
β Candidate's answer:
β’ Appearance: Annular, erythematous, scaly plaques (resembles subacute cutaneous lupus). Typically periorbital (raccoon eyes), scalp, face, neck, trunk, and extremities. Often photosensitive β appears or worsens with sunlight exposure.
β’ Onset: Usually appears in the first few weeks of life (as maternal antibodies circulate). Can be present at birth.
β’ Differential diagnosis: Seborrheic dermatitis, atopic dermatitis, tinea, erythema multiforme.
β’ Treatment:
- Sun avoidance (most important) β protect from direct sunlight; use SPF 50+ sunscreen, hats, long sleeves.
- Mild topical steroids (hydrocortisone 1% or desonide) for symptomatic lesions.
- No systemic steroids needed for isolated rash.
- Avoid phototherapy.
β’ Prognosis: Rash resolves spontaneously by 6-8 months of age as maternal antibodies are cleared. Does NOT cause scarring or permanent skin changes. No increased risk of developing SLE in childhood (very low risk).
β Q6 (Examiner): βWhat hematologic abnormalities occur in neonatal lupus? How are they managed?β
β Candidate's answer:
β’ Thrombocytopenia (low platelets) β most common hematologic manifestation. Can be severe (<20,000/ΞΌL) in rare cases, but usually mild.
β’ Neutropenia (low absolute neutrophil count) β usually asymptomatic.
β’ Anemia (hemolytic or hyporegenerative) β less common.
β’ Transient abnormal liver enzymes (mild transaminitis).
β’ Management:
- Usually self-limited and does not require treatment.
- Monitor CBC at birth and then weekly for first month, then monthly until normal.
- If severe thrombocytopenia (<20,000/ΞΌL) with bleeding (petechiae, bruising, intracranial hemorrhage rare): IVIG (1 g/kg/day for 2 days) or platelet transfusion. Rarely, steroids.
- Neutropenia does not require treatment unless fever or sepsis (then treat empirically).
- All cytopenias resolve by 3-6 months of age.
β Q7 (Examiner): βIs hydroxychloroquine safe during pregnancy and breastfeeding? Why is it recommended?β
β Candidate's answer:
β’ Safety: Hydroxychloroquine (HCQ) is safe and recommended during pregnancy and breastfeeding. Multiple studies show no increased risk of congenital malformations, miscarriage, or preterm birth. It is NOT teratogenic.
β’ Benefits during pregnancy:
- Reduces the risk of congenital heart block (CHB) by approximately 50% in mothers with anti-Ro/SSA antibodies.
- Reduces maternal disease flares (which can harm the pregnancy).
- Improves fetal outcomes (higher birth weight, lower prematurity).
β’ Breastfeeding: Only trace amounts pass into breast milk (less than 1% of maternal dose). Levels are far below the therapeutic dose for an infant and are considered safe.
β’ Recommendation: All pregnant women with SLE and anti-Ro/La antibodies should be on HCQ (200-400 mg daily) throughout pregnancy and breastfeeding, unless contraindicated (retinopathy β rare with long-term use).
β’ Ophthalmologic monitoring: Baseline and annual retinal exams for mother (very low risk with pregnancy duration).
β Q8 (Examiner): βWhat are the indications for pacemaker placement in a neonate with congenital complete heart block? What is the timing?β
β Candidate's answer:
β’ Absolute indications for pacing in a neonate with CHB:
- Ventricular rate <50-55 bpm (some centers use <55 bpm).
- Presence of symptoms: hydrops fetalis, heart failure, poor feeding, syncope, or poor growth.
- Long QT interval with pause-dependent arrhythmias.
- Wide QRS complex or complex ventricular ectopy.
- Neonates with structural heart disease plus CHB.
β’ Timing of pacemaker insertion:
- Neonatal period (first days to weeks of life) if above criteria are met.
- Asymptomatic neonates with heart rate >55-60 bpm may be observed without immediate pacing, but require close monitoring (Holter, echocardiogram). Many will eventually need pacing within the first few months or years of life as the heart rate drops or symptoms develop.
β’ Approach: Epicardial pacemaker (leads placed on the heart surface via sternotomy or subxiphoid approach). Transvenous pacing is not used in neonates due to small size.
β’ Prognosis with pacing: Excellent β normal growth, development, activity. Lifelong pacing required (battery changes every 5-10 years).
β Q9 (Examiner): βIf a baby is born with a normal heart rhythm but has anti-Ro/La antibodies, can they develop heart block later? What about later in childhood?β
β Candidate's answer:
β’ Risk is extremely low, but not zero.
β’ Late-onset CHB (after the neonatal period) is rare but has been reported. Maternal antibodies are cleared by 6-8 months; after that, the immune-mediated injury stops. However, if scarring occurred in utero without causing complete block, the conduction defect may progress gradually.
β’ Recommendation: All infants born to anti-Ro/La positive mothers should have a postnatal ECG within the first 2 weeks of life (to detect first-degree heart block) and possibly a Holter monitor.
β’ If the ECG is normal, the risk of developing CHB later in infancy is <0.5%.
β’ However, there are case reports of children developing heart block at 6-12 months of age, so some cardiologists recommend a follow-up ECG at 6-12 months.
β’ If there is any concern (syncope, poor feeding, fatigue), repeat ECG and Holter.
β’ Beyond 1-2 years of age, the risk is negligible.
β Q10 (Examiner): βWhat is the recurrence risk for a mother with anti-Ro/La antibodies who already had one child with congenital heart block? What can be done to prevent it in the next pregnancy?β
β Candidate's answer:
β’ Recurrence risk: Approximately 15-20% for another child with CHB (much higher than the 1-2% baseline).
β’ Prevention strategies for subsequent pregnancies:
- Hydroxychloroquine (HCQ) 400 mg daily β reduces recurrence risk by ~50% (from 20% to ~10%).
- Maternal dexamethasone if first-degree block is detected (as discussed), but does not prevent complete block in most cases.
- Frequent fetal echocardiography (weekly from 16 weeks) to detect early first-degree block.
- Intravenous immunoglobulin (IVIG) β given to mother at 12, 16, 20 weeks (1 g/kg) β some studies show reduced recurrence, but not yet standard; considered experimental.
- Avoid medications that cross the placenta unnecessarily.
β’ Counseling: Even with optimal management, recurrence cannot be completely prevented. Families should be prepared for possible pacemaker placement.
β’ Delivery planning: Deliver at a tertiary center with neonatal cardiology and cardiac surgery.
β Q11 (Examiner): βCan this mother breastfeed while taking prednisolone and hydroxychloroquine? Are there any contraindications?β
β Candidate's answer:
β’ Breastfeeding is strongly encouraged for mothers with SLE taking these medications.
β’ Prednisolone: Less than 1% of the maternal dose passes into breast milk. Doses up to 20-30 mg/day are considered safe. No adverse effects reported in breastfed infants. If the mother is on very high doses (>40 mg/day), wait 4 hours after dosing to breastfeed to minimize exposure, but even then, risk is negligible.
β’ Hydroxychloroquine: Trace amounts in breast milk (about 1% of maternal dose). No reports of toxicity in breastfed infants. The AAP considers it compatible with breastfeeding. Reassure the mother that the benefits of breastfeeding far outweigh any theoretical risk.
β’ Other lupus medications:
- Azathioprine: Safe in breastfeeding (low milk transfer).
- Cyclosporine/tacrolimus: Safe β low milk transfer.
- Mycophenolate mofetil: Generally avoided due to potential immunosuppression (limited data).
- Rituximab, cyclophosphamide: Not recommended during breastfeeding (avoid).
β’ Do NOT stop medications to breastfeed β uncontrolled lupus harms both mother and baby.
β Q12 (Examiner): βWill this child have an increased risk of developing SLE or another autoimmune disease later in life?β
β Candidate's answer:
β’ No, the risk is very low. Neonatal lupus is a passive transfer of antibodies, not active autoimmunity.
β’ Risk of SLE in childhood/adolescence: The child does not have an increased risk of SLE compared to the general population (about 0.02-0.05% risk).
β’ However, there is a slightly increased risk of developing autoimmune thyroid disease or autoantibodies (not full SLE), but the absolute risk is still low.
β’ If the child has a pacemaker for CHB: The heart block is permanent and irreversible, but it does not cause other autoimmune problems. The child will need lifelong cardiology follow-up but not rheumatology unless symptoms develop.
β’ Recommendation: No special screening for SLE is needed. The child should receive routine pediatric care. If the child develops prolonged fever, rash, arthritis, or other concerning symptoms, evaluate for autoimmune disease (but this is no different from any other child).
β’ Reassure the mother that her child will not "inherit" her SLE in the sense of active autoimmunity.
π£οΈ Examiner's probing / high-yield points (Maternal SLE & Neonatal Lupus):
β’ "What are the two most important antibodies?" β Anti-Ro/SSA and anti-La/SSB (IgG).
β’ "What is the most serious manifestation?" β Congenital heart block (CHB) β irreversible, may require pacemaker.
β’ "What is the risk of CHB?" β 1-2% (up to 5% in high-risk); recurrence 15-20%.
β’ "How do you monitor the fetus?" β Serial fetal echocardiography (16-28 weeks, weekly or biweekly).
β’ "What medication reduces the risk of CHB?" β Hydroxychloroquine (HCQ) β safe in pregnancy/breastfeeding.
β’ "How long do maternal antibodies persist in the infant?" β 6-8 months.
β’ "Is the rash permanent?" β No, resolves without scarring by 6-8 months.
β’ "Can the mother breastfeed?" β Yes, HCQ and prednisolone are safe.
π Definition Passive transfer of maternal anti-Ro/SSA and anti-La/SSB antibodies (IgG) across the placenta, causing transient or permanent injury to the fetus/neonate. NOT active SLE in the infant.
π Risk of CHB 1-2% per pregnancy; recurrence 15-20%. Higher with high anti-Ro52 titers, previous affected child. Hydroxychloroquine reduces risk by ~50%.
π Fetal Monitoring Serial fetal echocardiography (16-28 weeks, weekly/biweekly) to measure PR interval. Prolonged PR β first-degree block; may consider dexamethasone.
π Treatment & Prevention HCQ (hydroxychloroquine) safe in pregnancy/breastfeeding, reduces CHB risk. Dexamethasone for first-degree block (controversial). Pacemaker for complete heart block if ventricular rate <55 bpm or symptoms.
π€± Breastfeeding & Prognosis HCQ and prednisolone are safe in breastfeeding. Antibodies cleared by 6-8 months β rash and cytopenias resolve. No increased risk of SLE in later life. Pacemaker provides excellent long-term outcome.
β High-yield pearls for TOACS (Maternal SLE Counseling):
β’ Most important antibodies: Anti-Ro/SSA and anti-La/SSB.
β’ Most serious complication: Congenital heart block (CHB) β risk 1-2%.
β’ Fetal monitoring: Serial fetal echocardiography (16-28 weeks).
β’ Hydroxychloroquine (HCQ) is safe and reduces CHB risk.
β’ Rash and cytopenias are transient and resolve by 6-8 months.
β’ Breastfeeding is safe with HCQ and prednisolone.
β’ No increased risk of SLE in the child later in life.
β’ Pacemaker is needed for symptomatic complete heart block (heart rate <55 bpm).